Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as an oral formulation for oral use. It is employed in the treatment of chronic lymphocytic leukemia, Hodgkin's lymphoma and other lymphoid malignancies in adult patients.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leukeran (chlorambucil) is used in hematologic cancers that involve malignant lymphoid cells.

- Chronic lymphocytic leukemia: helps control disease progression and improve survival. - Hodgkin's lymphoma: used as part of combination therapy to achieve remission. - Other lymphoid malignancies: provides therapeutic benefit in selected non‑Hodgkin lymphomas and related disorders.

Leukeran may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after dosing. - Bone marrow suppression: anemia, leukopenia, and thrombocytopenia due to reduced blood cell production. - Alopecia: hair loss that is usually reversible after treatment. - Fatigue: general tiredness and reduced stamina. - Mild rash or itching: skin irritation at the site of drug exposure.

Serious or Rare Side Effects: - Secondary malignancies: increased risk of developing new cancers after prolonged use. - Severe myelosuppression: life‑threatening infections or bleeding due to profound blood count drops. - Pulmonary fibrosis: scarring of lung tissue causing breathing difficulties. - Hepatic toxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: anaphylaxis or serum sickness‑like symptoms. - Renal impairment: reduced kidney function in susceptible individuals.

When prescribing or handling Leukeran, several safety measures are recommended.

- Monitor blood counts: perform regular complete blood count tests to detect myelosuppression early. - Assess organ function: evaluate liver and kidney function before and during therapy. - Avoid use in active infections: postpone treatment if the patient has uncontrolled infections. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss alternatives with the prescriber. - Drug interactions: review concomitant medications for potential additive myelosuppressive effects. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Chlorambucil can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause severe infection due to immunosuppression. - Other alkylating agents: increase risk of severe bone marrow toxicity. - Warfarin: potentiates anticoagulant effect, raising bleeding risk. - CYP2D6 inhibitors: may raise chlorambucil plasma levels. - High‑dose folic acid: can reduce drug effectiveness.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Allopurinol: can enhance chlorambucil toxicity. - ACE inhibitors: monitor renal function and blood pressure. - Antifungal azoles: may affect drug metabolism. - Immunosuppressants: require careful blood count monitoring.